Centessa Pharmaceuticals plc
CNTA
$12.43
-$0.25-1.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -61.72% | -56.04% | -2.44% | 8.86% | 34.84% |
| Total Depreciation and Amortization | -7.80% | 60.00% | 108.20% | 165.28% | 266.43% |
| Total Amortization of Deferred Charges | -0.45% | -10.80% | 26.40% | 119.61% | 761.54% |
| Total Other Non-Cash Items | 618.91% | 705.61% | 597.68% | 336.09% | -53.58% |
| Change in Net Operating Assets | 67.41% | 217.71% | 77.95% | -27.95% | -234.48% |
| Cash from Operations | -8.16% | 11.40% | 27.95% | 19.85% | 24.49% |
| Capital Expenditure | 58.02% | 79.88% | 92.18% | 90.73% | 91.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -772.40% | 124.68% | 88.98% | 94.78% | 72.31% |
| Cash from Investing | -769.59% | 124.62% | 89.00% | 94.76% | 72.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,064.86% | 1,656.08% | 2,405.09% | 42,876.00% | 8,153.26% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,030.48% | 1,627.29% | 2,379.96% | 42,026.46% | 8,153.26% |
| Foreign Exchange rate Adjustments | -261.08% | 99.51% | -225.42% | -115.64% | -40.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 90.79% | 196.08% | 181.78% | 94.73% | 50.16% |